E123: Eye Exam Kiosks, Whoop for Fertility, and Elon’s xAI

Our Social Media Pages, follow us and engage with the Pill-grim community!Join our Entre CommunityInstagramTwitter YouTubeTikTokLinkedIn And now for this week’s prescription:On this week’s dose, we start (1:58) with a breakdown on Eyebot, a startup that’s building AI-powered kiosks that provide 90-second vision exams without the need for on-site optometrists, and their recent $6m funding round. Then (9:04), we discuss Natural Cycles, a company that provides women with an innovative, FDA cleared birth control option, hot off a $55M Series C. Lastly (15:27), we wrap up this week’s dose with a deepdive on xAI, Elon Musk’s new AI startup that plans to compete against other major players in the space, and their massive $6B Series B.  Sources:https://eyebot.co/https://techcrunch.com/2024/06/06/eyebot-raised-6m-for-ai-powered-kiosks-that-provide-90-second-eye-exams-without-optometrist/https://www.aoa.org/news/advocacy/federal-advocacy/part-of-the-solution-optometry-groups-join-aoa-in-submitting-actionable-solutions-for-workforce-shortages?sso=yhttps://www.naturalcycles.com/ https://athletechnews.com/birth-control-app-natural-cycles-lands-55m-womens-health/ https://x.ai/https://x.ai/blog/series-bhttps://techcrunch.com/2024/05/26/elon-musks-xai-raises-6b-from-valor-a16z-and-sequoia/https://techcrunch.com/2024/03/05/openai-response-elon-musk-lawsuit/https://www.techopedia.com/news/elon-musks-xai-raised-6b-in-latest-fundraising-roundMusic Credit: Chapter One by Cole Bauer and Dean Keetonhttps://www.instagram.com/colebauer/https://www.instagram.com/deankeeton/?hl=enDisclosure:The views, statements, and opinions, expressed herein by the hosts and guests are their own, and their appearance on the podcast should not be construed as reflecting the views or implied endorsement of Independent Brokerage Solutions LLC or any of its officers, employees, or agents. The statements made herein should not be considered an investment opinion, advice, or a recommendation regarding securities of any company. This podcast is produced solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy a security.